BMS’s Zenbexus meets PFS endpoint in pivotal multiple myeloma trial
Phase 3positiveZenbexusPositive
AI Analysis
Summary
Bristol Myers Squibb's Zenbexus met the progression-free survival endpoint in a pivotal Phase 3 trial for multiple myeloma treatment.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
met PFS (progression-free survival) endpoint in pivotal trial
Importance:8/10
Sentiment:
0.80
multiple myelomaPhase 3pivotal trialPFS endpointpositive data
Related Companies
Read the original article
Published by yahoo_finance on October 8, 2026 4:55 PM